Glucocorticoid prescribing and cardiovascular risk in polymyalgia rheumatica and giant cell arteritis: analysis of routinely collected primary care data from the North of England

Clicks: 26
ID: 332506
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #32 of 143 articles by views in Rheumatology Advances in Practice

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are treated with long-term glucocorticoid therapy, which may increase the risk of cardiovascular disease (CVD). Patients with established CVD or with a 10-year CVD risk ≥10%, as estimated by the QRISK tool in primary care, should be offered statins. We aimed to characterise glucocorticoid prescribing and cardiovascular risk in a new primary care PMR/GCA cohort, using the Connected Bradford database. Methods We identified patients aged ≥50 years with a new diagnosis of PMR/GCA between 1st January 2000 and 31st December 2023, registered with a GP practice contributing to Connected Bradford for >6 months and with ≥2 glucocorticoid prescriptions post-diagnosis. Average cumulative prednisolone equivalent dose was calculated in 13-week blocks over a four-year follow-up period. To characterise CVD risk, prevalence of diabetes mellitus, atrial fibrillation, heart failure, peripheral arterial disease, hypertension and median QRISK3 scores were estimated on the date of PMR/GCA diagnosis. Results 4,105 patients with PMR and 700 with GCA were identified (66.5% female; mean age 73.6 years). Incidence was 6.27/10,000 person-years for PMR and 1.07/10,000 person-years for GCA. Over a third of the cohort were still prescribed glucocorticoids two years after PMR/GCA diagnosis. At cohort entry, median QRISK3 score was 29.5%, and 25.3% had pre-existing cardiovascular or cerebrovascular disease. Conclusion There was a considerable burden of CVD, reflected in high QRISK3 scores, alongside frequent prolonged glucocorticoid exposure, translating known excess cardiovascular risk in PMR/GCA into guideline-actionable clinical burden.
Reference Key
openalex_W7222319236 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Katrina Z Freimane, Timon Blakemore Kocadag, Oliver M. Todd, Max M. Yates, Kate Best, Kuldeep Sohal, Sarah Mackie
Are you one of these authors? Claim your profile
Journal Rheumatology Advances in Practice
Year 2026
DOI
10.1093/rap/rkag123
URL
https://academic.oup.com/rheumap/advance-article-pdf/doi/10.1093/rap/rkag123/71954823/rkag123.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.